Inventor
MARASCO AGOSTINO
IT29 patents
⚠️ This page may combine multiple inventors who share the name “MARASCO AGOSTINO”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
AUTIFONY THERAPEUTICS LTD
19 patentsUS10098881B2Oct 16, 2018
Compounds
AUTIFONY THERAPEUTICS LTD8 citations92
US9833452B2Dec 5, 2017
Compounds
AUTIFONY THERAPEUTICS LTD7 citations92
US9422272B2Aug 23, 2016
Compounds
AUTIFONY THERAPEUTICS LTD11 citations92
US9133175B2Sep 15, 2015
Compounds
AUTIFONY THERAPEUTICS LTD18 citations92
US10835534B2Nov 17, 2020
Compounds
AUTIFONY THERAPEUTICS LTD3 citations84
US10555945B2Feb 11, 2020
Compounds
AUTIFONY THERAPEUTICS LTD3 citations84
US9849131B2Dec 26, 2017
Imidazolidinedione derivatives
AUTIFONY THERAPEUTICS LTD4 citations83
US9216967B2Dec 22, 2015
Imidazolidinedione derivatives
AUTIFONY THERAPEUTICS LTD5 citations83
US9422252B2Aug 23, 2016
Triazoles as Kv3 inhibitors
AUTIFONY THERAPEUTICS LTD5 citations82
US10058551B2Aug 28, 2018
Imidazolidinedione derivatives
AUTIFONY THERAPEUTICS LTD3 citations72
US11197859B2Dec 14, 2021
Hydantoin derivatives useful as Kv3 inhibitors
AUTIFONY THERAPEUTICS LTD1 citations71
US10265316B2Apr 23, 2019
Hydantoin derivatives useful as Kv3 inhibitors
AUTIFONY THERAPEUTICS LTD1 citations71
US12358901B2Jul 15, 2025
KV3 modulators
AUTIFONY THERAPEUTICS LTD0 citations62
US11541052B2Jan 3, 2023
Compounds
AUTIFONY THERAPEUTICS LTD0 citations62
US11583527B2Feb 21, 2023
Hydantoin derivatives useful as Kv3 inhibitors
AUTIFONY THERAPEUTICS LTD0 citations61
US11180461B2Nov 23, 2021
Triazoles as Kv3 inhibitors
AUTIFONY THERAPEUTICS LTD0 citations61
US10611735B2Apr 7, 2020
Triazoles as Kv3 inhibitors
AUTIFONY THERAPEUTICS LTD0 citations50
US10160730B2Dec 25, 2018
Triazoles as KV3 inhibitors
AUTIFONY THERAPEUTICS LTD0 citations50
US10934278B2Mar 2, 2021
Compounds
AUTIFONY THERAPEUTICS LTD0 citations46
ALVARO GIUSEPPE
3 patentsNERRE THERAPEUTICS LTD
3 patentsUS9006271B2Apr 14, 2015
5-[5-[2-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropanomethylpropanoylmethylamino]-4-(4-fluoro-2-methylphenyl)]-2-pyridinyl-2-alkyl-prolinamide as NK1 receptor antagonists
NERRE THERAPEUTICS LTD0 citations51
US8822504B2Sep 2, 2014
5-[5-[2-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropanomethylpropanoylmethylamino]-4-(4-fluoro-2-methylphenyl)]-2-pyridinyl-2-alkyl-prolinamide as NK1 receptor antagonists
NERRE THERAPEUTICS LTD0 citations51
US8633214B2Jan 21, 2014
Spiro (piperidine-4,2′-pyrrolidine)-1-(3,5-trifluoromethylphenyl) methylcarboxamides as NK1 tachikynin receptor antagonists
NERRE THERAPEUTICS LTD0 citations48
GLAXO WELLCOME MFG PTE LTD
2 patentsUS8344005B2Jan 1, 2013
5-[5-[2-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropanoMethylpropanoylmethylamino]-4-(4-fluoro-2-methylphenyl)]-2 as NK1 receptor antagonists
GLAXO WELLCOME MFG PTE LTD5 citations81
US8367692B2Feb 5, 2013
Spiro (piperidine-4,2′-pyrrolidine)-1-(3,5-trifluoromethyl phenyl) methylcarboxamides as NK1 tachikynin receptor antagonists
GLAXO WELLCOME MFG PTE LTD0 citations46